Auto Amazon Links: No products found.
Barrett’s oesophagus affects an estimated one to two adults per 100, characterized by changes in the cells lining the oesophagus. Although most individuals with this condition do not develop cancer, the demand for NHS endoscopy services remains high. This has resulted in some patients not receiving monitoring as frequently as guidelines suggest.
The National Institute for Health and Care Excellence (NICE) indicates that the sponge test, which is already available in select locations, could offer reassurance to a greater number of patients. This test involves swallowing a small capsule attached to a thread, which dissolves once it reaches the stomach and releases a tiny sponge. As the sponge is gently pulled back out through the mouth, it collects cells from the oesophageal lining for analysis.
According to Prof Jonathan Benger, chief executive of NICE, these sponge tests provide a “quick and less invasive” option to detect concerning cellular changes. This method supports early identification of individuals who may require additional tests or treatment. Meanwhile, Prof Peter Johnson, national clinical director for cancer at NHS England, highlighted that thousands have already benefited from pilot programs using the test. He commented, “The NHS is always looking for better ways to get to the bottom of people’s symptoms … it’s fantastic it is now being considered for roll out across the country.”
Despite the advantages of the sponge test, NICE stresses that, like any diagnostic tool including endoscopy, it does not catch every case. Patients who receive a normal result on the sponge test should continue to undergo long-term monitoring. The sponge test is particularly useful for detecting both oesophageal cancer and Barrett’s oesophagus in individuals with reflux disease. NICE is expected to issue final recommendations on the use of the test early next year
Read the full article from The BBC here: Read More
Auto Amazon Links: No products found.